<DOC>
	<DOC>NCT01707628</DOC>
	<brief_summary>The purpose of this study is to compare the number of responders to vaccination with the influenza virus vaccine at different time points after last dose of rituximab in patients with lymphoma. Secondly to study the immune-response to vaccination with influenza virus vaccine, after treatment with rituximab in relation to the reconstitution of immune-function.</brief_summary>
	<brief_title>Response to Influenza Vaccination in Lymphoma Patients Treated With Rituximab</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Lymphoma, Non-Hodgkin</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Rituximab</mesh_term>
	<criteria>1. Patients with nonHodgkin's lymphoma, treated with rituximab (with a range of 612 cycles) and who are in remission. 2. Completion of rituximab therapy in the last twelve months before start of the study. 3. Age â‰¥ 18 years. 4. Signing of informed consent. 1. Completion of rituximab therapy 78 months before start of the study. 2. Fever at time of vaccination. 3. Previous/known allergic reaction to any of the components of the vaccines given.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>NHL</keyword>
	<keyword>influenza vaccination</keyword>
	<keyword>rituximab</keyword>
</DOC>